Gilead Sciences Inc

• Gilead pulled back due to profit-taking following a sustained multi-month rally. • Strong second-quarter revenue was driven by flagship HIV and Trodelvy franchises. • Analysts maintain Buy ratings with an average price target of $157.79.

• Gilead raised full-year sales guidance driven by accelerated HIV portfolio growth. • A federal court injunction blocked foreign importation to protect core market share. • Analysts issued Buy ratings with an average price target of $157.79.

• A federal court injunction blocks foreign importation of Gilead's key HIV medications. • Robust base-business revenue growth and raised guidance drove positive market sentiment. • Strategic oncology investments and bullish institutional options activity supported equity momentum.

• McKesson reported fiscal first-quarter earnings exceeding consensus expectations across core metrics. • Management raised full-year earnings guidance, citing strength in oncology and biopharma services. • The company leads its industry with $403.43 billion in latest annual revenue.

• Bristol-Myers Squibb lowered its financial outlook due to high costs replacing aging drugs. • Investors are concerned about slow adoption rates for the company's new product launches. • Federal drug pricing negotiations create valuation uncertainty and a price ceiling for shares.

• Amgen shares rose following strong quarterly earnings and increased full-year guidance. • Positive clinical trial updates for the obesity drug MariTide boosted investor confidence. • Analysts raised price targets citing improved margins and robust product portfolio growth.